Akorn Pharmaceuticals

Akorn Investor Relations

SEC Filings

Filing date Form Description Filing Group View
DEFA14A

Additional proxy soliciting materials - definitive

Proxy Filings
8-K

Report of unscheduled material events or corporate event

Current Reports
SC 13D/A

An amendment to a SC 13D filing

Other
DEFA14A

Additional proxy soliciting materials - definitive

Proxy Filings
10-Q

Quarterly report which provides a continuing view of a company's financial position

Quarterly Filings
EX-101.INS - XBRL INSTANCE DOCUMENT
SC 13D

Filing by person(s) reporting owned shares of common stock in a public company >5%

Other
3

Initial filing by director officer or owner of more than ten percent.

3,4,5
S-8 POS

Post-effective amendment to an S-8 filing

Registration Statements
S-8

Securities offered to employees pursuant to employee benefit plans

Registration Statements
4

Statement of changes in beneficial ownership of securities

3,4,5